Rocket Pharmaceuticals, Inc. (RCKT)

Market Cap	330.76M
Revenue (ttm)	n/a
Net Income (ttm)	-258.03M
Shares Out	107.74M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,287,095
Open	3.000
Previous Close	3.030
Day's Range	2.925 - 3.190
52-Week Range	2.190 - 26.980
Beta	0.68
Analysts	Buy
Price Target	19.68 (+541.04%)
Earnings Date	Aug 4, 2025

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 299
• Stock Exchange: NASDAQ
• Ticker Symbol: RCKT
• Website: https://www.rocketpharma.com

Analyst Forecast

According to 11 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is $19.68, which is an increase of 541.04% from the latest price.

Price Target

$19.68

(541.04% upside)

Analyst Consensus: Buy